Accordingly, among familial non-BRCA1/2 breast cancer patients, ELAVL1 can be used as an independent prognostic factor, associated with low survival rate and high tumor malignancy (Heinonen et al., 2007). Here, ELAVL1 is linked to breast carcinoma.